Q3
BDX — Q3 2026 Financial Report Analysis
In its first full quarter after spinning off its Life Sciences business to Waters, BD grew fiscal Q3 2026 revenue 5.4% (4.4% currency-neutral) to $4.98B, but tariffs, labour costs and FDA-related costs cut operating margin to 13.3%; buybacks lifted diluted EPS from continuing operations 4.5% to $1.64.